HIGHLIGHTS
- who: Gerald T. Nepom from the EpiVax, United States University of Alberta, Canada have published the research work: Synergistic targeting of immunologic pathways to empower durable tolerance therapies, in the Journal: (JOURNAL) of 02/09/2022
- future: Achieving durable immunological perturbation induced by targeted therapy and aligning these changes with clinical remission in the absence of general immunosuppression is informing and defining a future for successful immune tolerance.
SUMMARY
Important implications that derive from this frontiersin.org 10.3389/fimmu.2022.962177 benefit from drug administration, and a post-hoc analysis . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.